Advanced in AIDS Dysmorphic Syndrome

Lee Fairlie

Johannesburg, GT, ZA 
Advanced in AIDS Dysmorphic Syndrome
Johannesburg, GT, ZA 
OverviewLocationsClinical Research

Overview

Lee Fairlie practices in Johannesburg, South Africa. Mr. Fairlie is rated as an Advanced expert by MediFind in the treatment of AIDS Dysmorphic Syndrome. His top areas of expertise are HIV/AIDS, AIDS Dysmorphic Syndrome, Severe Acute Respiratory Syndrome (SARS), and HELLP Syndrome.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of AIDS Dysmorphic Syndrome.

Gender
Male

Locations

Johannesburg, GT, South Africa
Other Locations
Port Elizabeth, Wits Health Consortium, Johannesburg And The Tuberculosis And HIV Investigative Network, Durban, ZN, South Africa
University Of Cape Town, Cape Town, Stellenbosch, WC, South Africa
22 Esselen Street, 2001, South Africa
Groote Schuur Hospital And The University Of Cape Town, Cape Town, WC, South Africa

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Drugs: Dolutegravir, ABC/DTG/3TC
Study Phase: Phase 3
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir, Tenofovir Alafenamide, Truvada, Atripla
Study Phase: Phase 3
A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa
A Phase II, Observer-blinded, Randomized, Active-controlled Study to Examine the Immunogenicity and Safety of Rotarix® and RV3-BB When Co-administered/Boosted With Trivalent P2-VP8 Subunit Rotavirus Vaccine Candidate in Healthy Infants in South Africa
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Biological
Study Phase: Phase 2
Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)
Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)
Enrollment Status: Completed
Publish Date: August 01, 2022
Intervention Type: Biological
Study Drug: Ad26.COV2.S COVID-19 vaccine
Study Phase: Phase 3
View 3 Less Clinical Trials

120 Total Publications

Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis.
Factors Predictive of Early Discontinuation of Preventive Treatment in Children With Household Exposure to Multidrug-resistant Tuberculosis.
Journal: Open forum infectious diseases
Published: June 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fairlie's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile